Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.
Zilan ZhouMina JafariVishnu SriramJinsoo KimJoo-Youp LeeSasha J Ruiz-TorresSusan E WaltzPublished in: Molecular pharmaceutics (2017)
There are an increasing number of studies showing the order of drug presentation plays a critical role in achieving optimal combination therapy. Here, a nanoparticle design is presented using ion pairing and drug-polymer conjugate for the sequential delivery of gefitinib (Gi) and doxorubicin (Dox) targeting epidermal growth factor receptor (EGFR) signaling applicable for the treatment of triple negative breast cancers. To realize this nanoparticle design, Gi complexed with dioleoyl phosphatidic acid (DOPA) via ion paring was loaded onto the nanoparticle made of Dox-conjugated poly(l-lactide)-block-polyethylene glycol (PLA-b-PEG) and with an encapsulation efficiency of ∼90%. The nanoparticle system exhibited a desired sequential release of Gi followed by Dox, as verified through release and cellular uptake studies. The nanoparticle system demonstrated approximate 4-fold and 3-fold increases in anticancer efficacy compared to a control group of Dox-PLA-PEG conjugate against MDA-MB-468 and A549 cell lines in terms of half maximal inhibitory concentration (IC50), respectively. High tumor accumulation of the nanoparticle system was also substantiated for potential in vivo applicability by noninvasive fluorescent imaging.
Keyphrases
- epidermal growth factor receptor
- cancer therapy
- drug delivery
- combination therapy
- iron oxide
- small cell lung cancer
- tyrosine kinase
- advanced non small cell lung cancer
- high resolution
- risk assessment
- squamous cell carcinoma
- quantum dots
- photodynamic therapy
- radiation therapy
- signaling pathway
- case control
- breast cancer cells
- high intensity
- adverse drug